Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients

New advances in acute myeloid leukemia (AML) therapies, plus the development of predictive and prognostic factors, are allowing for the individualization of therapy for patients with AML. This symposium will focus on the dramatic and rapid changes occurring in the treatment of AML and will feature didactic presentations combined with interactive discussion with an expert panel.

Register Now

Friday Satellite Symposium preceding the 59th ASH Annual Meeting & Exposition.


Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients

  • 6:30 PM: Program Overview: Therapeutic Breakthroughs in AML
  • 6:45 PM: Expanding the Testing Data Considered in Making Informed Treatment Decisions
  • 7:15 PM: Managing Newly Diagnosed AML: Treatment Considerations to Personalize Care
  • 8:00 PM: Relapsed/Refractory AML: Considerations and Challenges
  • 8:45 PM: Integrating Emerging Targeted Therapies Into AML Treatment Strategies
  • 9:15 PM: Question and Answer Session and Closing Remarks


Date / Time
Event Details


Program Director
Jeffrey E. Lancet, MD

Senior Member & Professor
 Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Gail J. Roboz, MD

Director, Clinical and Translational Leukemia Programs
Professor of Medicine
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York

B. Douglas Smith, MD

Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Roland Walter, MD, PhD, MS

Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Associate Professor of Medicine
Division of Hematology/Department of Medicine
University of Washington School of Medicine
Adjunct Associate Professor
Department of Epidemiology
University of Washington School of Public Health
Seattle, Washington


Goal Statement
The goal of this activity is to help participants align their clinical practice with practice-changing findings and current guidelines for the treatment of acute myeloid leukemia.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with acute myeloid leukemia.

Learning Objectives

  • Identify prognostic or therapeutically relevant molecular (genetic, epigenetic, protein) features or aberrations in AML and describe their clinical importance in terms of risk prediction, diagnosis, and prognosis
  • Summarize current evidence on the benefits of standard chemotherapy-based protocols and emerging therapies for the treatment of AML, including in elderly patients, those with relapsed/refractory disease, or patients with poor-risk cytogenetics
  • Discuss emerging safety and efficacy data and ongoing clinical trials evaluating next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents for patients with AML who may not benefit from standard therapy
  • Identify patients with AML who may benefit from enrollment in clinical trials evaluating next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents


Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.